Lineage Cell Therapeutics, Inc. (LCTX) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies. Its lead program, OpRegen (for geographic atrophy), is in Phase 2a development under a collaboration with Roche/Genentech. Other programs include OPC1 (spinal cord injury), ReSonance (hearing loss), and newly launched preclinical programs COR1 (corneal disease) and ILT1 (islet cell manufacturing). The company operates as a single segment and is classified as a smaller reporting company.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $1,725 | $1,502 |
| Net Loss Attributable to Lineage | $(4,812) | $(4,139) |
| Net Loss Per Share (Diluted) | $(0.03) | $(0.02) |
| Operating Cash Flow | $(8,078) | $(4,886) |
| Cash, Cash Equivalents & Marketable Securities | $53,381 | $N/A |
| Warrant Liability | $34,140 | $43,906 |
| Accumulated Deficit | $(471,810) | $(407,604) |
Note: Cash and marketable securities total $53.4 million as of March 31, 2026 ($35.9M cash + $17.4M marketable securities).
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 15% to $1.7 million, driven by a 24% increase in collaboration revenues ($1.6M vs $1.3M). This was primarily due to revenue recognized under the new research collaboration with William Demant Invest 2 Aps (WDI) for the ReSonance program.
- Expense Increases: Operating expenses rose 16% to $9.3 million. Research and Development (R&D) expenses increased 36% to $4.2 million, reflecting expanded activities in the OPC1, ReSonance, and new COR1/ILT1 programs. General and Administrative (G&A) expenses increased 5% to $5.1 million.
- Warrant Liability Reduction: The fair value of warrant liabilities decreased by $9.8 million (from $43.9M to $34.1M), resulting in a non-cash gain of $2.3 million in the income statement. This reduction was driven by warrant exercises ($5.4M proceeds) and a decrease in the company's stock price.
- Cash Flow: Net cash used in operating activities increased to $8.1 million from $4.9 million, largely due to a reduction in accounts payable and deferred revenue, partially offset by non-cash adjustments.
Guidance, Outlook, and Risks
- Liquidity: Management believes current cash and marketable securities ($53.4 million) are sufficient to fund operations for at least the next 12 months. The company expects to continue incurring significant losses.
- Capital Resources: The company raised $5.4 million in Q1 2026 from warrant exercises. Up to $30.2 million remains available from the full exercise of outstanding warrants from the November 2024 Registered Direct Offering (RDO). Additionally, $60.0 million remains available under the At-The-Market (ATM) offering program.
- Geopolitical Risk: The filing highlights significant risks related to the escalation of conflict in the Middle East (strikes on Iran commencing Feb 28, 2026). All manufacturing is conducted at the subsidiary facility in Jerusalem, Israel. While operations were not materially disrupted as of the filing date, potential military call-ups of employees and infrastructure disruptions pose a material risk.
- Regulatory Environment: The company notes potential impacts from U.S. federal policy changes, including reduced FDA staffing and funding, which could delay regulatory reviews.
- Legal Proceedings: A shareholder (HBL) initiated a books and records request regarding an intercompany agreement. A third-party valuation firm opined the consideration was insufficient, and the court granted the motion to terminate proceedings to allow for separate litigation. No material litigation is currently pending.
Investor Verification Checklist
- Manufacturing Continuity: Verify the operational status of the Jerusalem facility and employee availability given the ongoing regional conflict and potential military call-ups.
- Warrant Exercise Potential: Assess the likelihood of the remaining $30.2 million in warrant exercises occurring, given the current stock price relative to the $0.91 exercise price.
- Collaboration Milestones: Monitor the progress of the OpRegen Phase 2a "GAlette" study and the potential for future milestone payments from Roche, which are subject to IIA redemption fees (approx. 24.1%).
- Burn Rate: Confirm the sustainability of the current cash burn rate (~$8M operating cash outflow per quarter) against the $53.4M liquidity position.
- Legal Exposure: Track the status of the HBL shareholder dispute regarding the intercompany agreement valuation.